NASDAQ:IMGN - ImmunoGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.25 +0.28 (+2.81 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$9.97
Today's Range$9.95 - $10.37
52-Week Range$4.80 - $13.41
Volume2.94 million shs
Average Volume3.01 million shs
Market Capitalization$1.34 billion
P/E Ratio-13.60
Dividend YieldN/A
ImmunoGen logoImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-0.06
Current Ratio3.74
Quick Ratio3.73


Trailing P/E Ratio-13.60
Forward P/E Ratio-8.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$115.45 million
Price / Sales11.81
Cash FlowN/A
Price / CashN/A
Book Value($0.14) per share
Price / Book-73.21


EPS (Most Recent Fiscal Year)($0.75)
Net Income$-96,010,000.00
Net Margins-109.85%
Return on EquityN/A
Return on Assets-39.05%


Outstanding Shares133,040,000
Market Cap$1,338.35

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, May, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.03. The biotechnology company had revenue of $19.80 million for the quarter, compared to analysts' expectations of $15.04 million. The company's revenue for the quarter was down 30.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.20) EPS. View ImmunoGen's Earnings History.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for ImmunoGen.

What price target have analysts set for IMGN?

7 brokers have issued 1 year target prices for ImmunoGen's stock. Their predictions range from $5.00 to $20.00. On average, they anticipate ImmunoGen's stock price to reach $13.60 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Ratings for ImmunoGen.

What is the consensus analysts' recommendation for ImmunoGen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:
  • 1. According to Zacks Investment Research, "ImmunoGen is heavily dependent on its lead ovarian cancer candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. On the flip side, the company has made a significant progress with mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, the company’s high dependence on its partnerships for revenue is concerning. The company’s shares have outperformed the broader industry in a year's time. Estimates have been stable lately ahead of the company’s Q1 earnings release." (4/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
  • 3. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:
  • Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
  • Mr. David B. Johnston, Exec. VP & CFO (Age 63)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 63)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)

Has ImmunoGen been receiving favorable news coverage?

Media headlines about IMGN stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ImmunoGen earned a news impact score of 0.16 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.25 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.07%), Baxter Bros Inc. (0.02%), Creative Planning (0.02%), Xact Kapitalforvaltning AB (0.02%) and Amalgamated Bank (0.01%). Company insiders that own ImmunoGen stock include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Baxter Bros Inc.. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Creative Planning, Amalgamated Bank and Xact Kapitalforvaltning AB. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $10.25.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $1.34 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]

MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  640
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.